Abbott Laboratories Corporation

Abb Vie Deutschland Gmbh & Co. Kg

Abbott Gmbh & Co Kg

Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Min Zhang

Liliane Unger

Andreas Haupt

Karsten M Wicke

Ana-Lucia Relo

Frauke Pohlki

Karla Drescher

Anton Bespalov

Wilfried Martin Braje

Sean Colm Turner

Gisela Backfisch

Juergen Delzer

Barbara Vogg

Stevan Wakefield Djuric

Alan Frank Gasiecki

Irini Akritopoulou-Zanze

Shashank Shekhar

Noel S Wilson

Hongyu H Zhao

Dennie S Welch

Albert Wayne Kruger

Jorge Gandarilla

Christina M Thompson

Huanqiu Li

Yanbin Lao

Ana Lucia Relo

Wolfgang Wernet

Udo Lange

Mario Mezler

Matthias Mayrer

Ana Lucia Jongen-Relo

Hongyu Zhao

Shashank Shekar

The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R, R, R, R, R, A, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Modulators of 5-HT receptors and methods of use thereof

The present invention relates to benzenesulfonyl or sulfonamide compounds of formulae IA and IB wherein the variables have the meanings given in the claims and the description, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HTreceptor.

[object Object]

The present invention relates to N-Phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds of formula I wherein the variables have the meanings given in the claims and the description, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HTreceptor.

The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I' and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HTreceptor. 

The present invention relates to N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HTreceptor.

N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

The present invention relates to N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HTreceptor. 

Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

Growing community of inventors

Abbott Park, IL, United States of America

Min Zhang